ROCHE HLDG DR (RHO5 HM) stock market data APIs
€345.1809
-0.53(-0.2%)
as of December 22, 2025
Try our APIs with
free plan!
ROCHE HLDG DR Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for RHO5.HM.
Prev. Close
345.1809
Open
344.6558
High
346.9131
Low
342.6337
52 wk Range
235.4067-348.1
Market Cap
312 681 M
Dividends (Yield)
0.0415
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ROCHE HLDG DR data using free add-ons & libraries
Get ROCHE HLDG DR Fundamental Data
ROCHE HLDG DR Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ROCHE HLDG DR News
New
Health Care Roundup: Market Talk
Find insight on TrumpRx, Samsung Biologics and more in the latest Market Talks covering Health Care. Continue Reading
FDA Approves Genentech’s Lunsumio VELO™ for Subcutaneous Use in Relapsed or Refractory Follicular Lymphoma
– Lunsumio VELO reduces administration time from 2-4 hours to approximately one minute – – Availability of Lunsumio VELO allows treatment aligned to people’s clinical needs and personal prefe...
FDA approves Roche’s Lunsumio VELO™ for subcutaneous use in relapsed or refractory follicular lymphoma
F. Hoffmann-La Roche Ltd Lunsumio VELO reduces administration time from 2-4 hours to approximately one minute Availability of Lunsumio VELO allows treatment aligned to people’s clinical needs and p...
Is Switzerland losing its place in the world?
It was a remarkably blunt public warning from the top of Switzerland’s biggest bank. UBS chair Colm Kelleher declared last month that PREMIUM Upgrade to read this Financial Times article and get s...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
